Irrfan Khan had last month announced he has been diagnosed with neuroendocrine tumour and that he was going out of the country for treatment
Arunoday Singh
ADVERTISEMENT
Actor Arunoday Singh says his "Blackmail" co-star Irrfan Khan, who is currently in treatment for a "rare disease", is a strong man. He has urged people to stop speculating about his health. On the speculations being made on Irrfan's health, Arunoday told IANS over phone from Mumbai: "Just give the man some time to face it. It is his life. Let him just face it. He is a strong man and just pray for him. We do not need to speculate. You just need to send him good wishes. Whatever happened to that?"
Irrfan had last month announced he has been diagnosed with neuroendocrine tumour and that he was going out of the country for treatment. Speculations on his health have continued ever since. Arunoday says Irrfan, with whom he also worked with in "Yeh Saali Zindagi" in 2011, has not changed over the years.
"I did 'Yeh Saali Zindagi' with him a couple of years ago. He is exactly the same. He is much more successful, but he is exactly the same. He is as wonderful and as down to earth as a man," he added. Arunoday's latest release "Blackmail", a dark comedy, collected Rs 2.81 crore on its opening day.
Ecstatic over the film's response, Arunoday said: "It is lovely. It is very humbling but lovely. I am glad that a lot of people like the film and everyone worked very hard on it and it's nice to see. It's really nice to be a part of that."
Catch up on all the latest entertainment news and gossip here. Also download the new mid-day Android and iOS apps to get latest updates
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
